Objectives There is a need for effective and safe treatment during pregnancy in women with
chronic inflammatory diseases. This study evaluated placental transfer of certolizumab pegol …

Background Women with chronic inflammatory diseases face uncertainty regarding the
safety of biologics during breast feeding. CRADLE was the first industry-sponsored study to …

Objective Anti–tumor necrosis factor (anti‐ TNF ) medications are effective in controlling chronic
inflammatory diseases, but information about their use and safety in pregnancy is limited…

Objective. To provide information on pregnancy outcomes in women receiving certolizumab
pegol (CZP). Methods. The UCB Pharma safety database was searched for pregnancies …

Objectives To examine the safety and efficacy of 5-year administration of certolizumab
pegol (CZP)+methotrexate (MTX) in patients with active rheumatoid arthritis (RA). Methods …

The authors evaluate the human safety, tolerability, pharmacokinetics, and pharmacodynamics
of TZP‐101, an agonist of the hGHS‐R1a (ghrelin) receptor. Healthy subjects were …

After bilateral infusions of colchicine or vehicle in the rat nucleus basalis magnocellularis,
the time course of changes in several cholinergic and neurotrophin-related markers were …

Background and objective: TZP-101 is a selective, small molecule ghrelin receptor agonist
in clinical development for the treatment of gastric motility disorders. The objectives of this …

Abstract Development of therapeutics for Alzheimer’s disease (AD) requires appropriate cell
culture models that reflect the errant biochemical pathways and animal models that reflect …

Colchicine and ibotenic acid were compared for their ability to produce neurodegeneration
and cognitive deficit after bilateral infusions into the nucleus basalis magnocellularis of male …